CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a single arm, phase II trial of combined neoadjuvant platinum doublet chemotherapy
plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13
cycles for patients with potentially resectable stage IIIA and IIIB (T1-3, N2) NSCLC (per the
8th International Association for the Study of Lung Cancer classification). The primary
objective of this study is to increase N2 nodal clearance (N2NC) to 50% or greater for
combined platinum doublet chemotherapy with durvalumab induction therapy from historical rate
of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage
IIIA/B (N2) NSCLC.